- B2B biotech company Jellatech has secured $3.5 million in an oversubscribed seed round to build up its business of producing animal-free collagen, gelatin and other proteins.
- Denmark-based byFounders led the round with participation from Milano Investment Partners, Joyful VC, Siddhi Capital, and Blustein.
- Jellatech will use the new capital to scale up its cellular agriculture process, make new hires, and eventually commercialize its products.
Enter Jellatech. Founded in 2020, the US-based startup is developing bio-identical animal proteins beginning with collagen.
In 2022, the company said it had successfully produced collagen identical to its conventional animal-based counterpart using proprietary cell lines. This collagen could in theory be used in pharmaceuticals and food as well as cosmetics and dermatology.
Jellatech will use the oversubscribed seed round to fuel further R&D as well as scale up its cell-ag process and expand its team.
The company said it will also establish “key strategic partnerships” as it travels the road to commercialization.
Read More HERE